Exploiting mechanisms of signaling regulation with new pharmacology to develop novel cancer therapies
The success of targeted therapies depends on effective suppression of oncogenic signaling in tumors at doses tolerated by normal tissues. In the Poulikakos lab, we study the mechanisms that widen this window, identifying tumor-normal signaling and state asymmetries beyond mutation selectivity. These asymmetries can be exploited with new pharmacology, including conformation-selective inhibitors and induced-proximity approaches such as molecular glues and PROTACs, for tumor-selective inhibition. We further study how tumors escape targeted therapies, and use this understanding to design more effective treatments for RAS-, BRAF- and CDK-driven cancers.
1. Mechanisms of Drug Action and Tumor-Selective Pathway Inhibition
We define the conformational, structural and kinetic determinants of targeted inhibitor action, and the tumor-normal asymmetries that set their therapeutic index. Our discovery of RAF inhibitor-induced RAF dimerization and transactivation established that RAS activity and RAF dimer state determine both the tumor selectivity and the toxicity of first-generation RAF inhibitors (Nature, 2010), explaining their success in BRAF-mutant melanoma and other cancers, and predicting RAF dimerization as the predominant mechanism of resistance to these drugs.
We subsequently discovered the structural basis of dimer selectivity of RAF inhibitors and developed an integrated model of RAF inhibitor action predicting their biochemical properties and their clinical activity based on tumor context (Cancer Cell, 2016). These studies guided the preclinical and clinical development of next-generation RAF inhibitors. More recently, we identified molecular determinants of antitumor potency and predicted therapeutic window of paralog- and state-selective RAS inhibitors (Molecular Cancer Research, 2026) and identified binding kinetics as a source of tumor-selective MAPK suppression by a novel RAF inhibitor in RAS-mutant cancers (Science, in press).
2. Adaptive and Acquired Resistance to Targeted Therapies
We study the mechanisms by which RAS-mutant and BRAF-mutant tumors escape pathway inhibition, including feedback reactivation and alternative signaling complexes. We identified aberrantly spliced BRAF(V600E) dimers as a mechanism of acquired RAF inhibitor resistance in patients (Nature, 2011). We showed that SHP2 drives adaptive resistance to MAPK pathway inhibition in molecularly defined tumor subsets, and defined the contexts in which targeting SHP2 would be most effective (Cell Reports, 2019).
We further exploited allosteric properties of RAF and MEK inhibitors to design tumor-selective and effective inhibitor combinations against therapy-resistant BRAF-driven tumors (Cancer Discovery, 2021) and identified a previously unrecognized CDK6 conformational state that drives tumor insensitivity to CDK4/6 inhibitors and represents a new therapeutic target (Nature Cancer, 2021).
3. New Pharmacology for Tumor-Selective Inhibition
We identify mechanistic sources of therapeutic index that can be exploited using new pharmacologic modalities. We combine conformation-selective inhibitors, rational drug combinations and induced-proximity approaches to achieve tumor-selective suppression of oncogenic signaling.
We identified a difference in RAF conformational state between RAS-mutant and normal cells that can be exploited by conformation-selective RAF inhibitors. Combining such inhibitors with a RAF/MEK molecular glue, which spatially modulates RAF, enabled full-dose combination and potent RAS-mutant tumor-selective MAPK and growth inhibition (Cancer Discovery, 2026). We further developed bifunctional CDK4/6 degraders (PROTACs) that served both as mechanistic tools and as next-generation therapeutic prototypes (Nature Cancer, 2021).
Lab Members
Postdoctoral Fellows: Bijaya Gaire, PhD; Mathieu Desaunay, PhD; Ziyue Kou, PhD
Graduate Student: Beau Baars
Visit the Poulikakos Laboratory